The findings of Tiago et al. imply that, clinically, NR2F1 marks invasive, drug-tolerant melanoma cells that persist after therapy, driving relapse, and that cotargeting mTORC1 and MAPK pathways may improve outcomes, especially in older patients with resistant disease. The gene discussed is NR2F1; the disease is melanoma.